[68Ga]Ga-FAPI PET 评估消化系统肿瘤:系统评价与荟萃分析
该系统评价与荟萃分析检索了截至2022年8月12日的文献,最终纳入22项研究进行系统评价、18项研究进行荟萃分析,共524例消化系统肿瘤患者、459个原发肿瘤病灶和1921个转移病灶。基于患者的[68Ga]Ga-FAPI PET诊断消化系统肿瘤的敏感度为0.98(95% CI:0.94-0.99);基于病灶,原发病灶敏感度为0.97(95% CI:0.93-0.99),非原发病灶(淋巴结转移和远处转移)敏感度为0.94(95% CI:0.79-0.99)。作者认为[68Ga]Ga-FAPI PET在消化系统肿瘤诊断评估中具有高准确度,临床医生、核医学医师和放射科医师可考虑将其用于原发肿瘤、淋巴结转移和远处转移的评估。
要点
- 基于患者,[68Ga]Ga-FAPI PET诊断消化系统肿瘤的敏感度为0.98(95% CI:0.94-0.99)。
- 基于病灶,原发肿瘤病灶敏感度为0.97(95% CI:0.93-0.99)。
- 非原发病灶(淋巴结转移和远处转移)敏感度为0.94(95% CI:0.79-0.99)。
核心结论
- [68Ga]Ga-FAPI PET对消化系统肿瘤的诊断评估具有高准确度,其敏感度处于高水平。
- 临床医生、核医学医师和放射科医师可考虑使用[68Ga]Ga-FAPI PET/CT或PET/MR评估消化系统肿瘤的原发肿瘤、淋巴结转移和远处转移。
研究设计与样本
- 系统评价与诊断试验荟萃分析,检索PubMed、MEDLINE和Cochrane Library数据库自建库至2022年8月12日的文献。
- 共检索到541项研究,最终22项研究纳入系统评价,其中18项纳入荟萃分析。
- 荟萃分析共纳入524例消化系统肿瘤患者、459个消化系统肿瘤原发肿瘤病灶和1921个消化系统肿瘤转移病灶。
- 由3名研究者进行筛选和全文审阅,2名研究者进行数据提取,采用QUADAS-2标准评估偏倚风险,采用随机效应模型进行诊断试验荟萃分析。
主要发现
- 基于患者,[68Ga]Ga-FAPI PET诊断消化系统肿瘤的敏感度为0.98(95% CI:0.94-0.99)。
- 基于病灶,[68Ga]Ga-FAPI PET诊断评估消化系统原发肿瘤病灶的敏感度为0.97(95% CI:0.93-0.99)。
- 基于病灶,[68Ga]Ga-FAPI PET诊断评估消化系统肿瘤非原发病灶(淋巴结转移和远处转移)的敏感度为0.94(95% CI:0.79-0.99)。
关键数值与推荐
- 基于患者,[68Ga]Ga-FAPI PET诊断消化系统肿瘤的敏感度为0.98(95% CI:0.94-0.99)。
- 基于病灶,原发肿瘤病灶的敏感度为0.97(95% CI:0.93-0.99)。
- 基于病灶,非原发病灶(淋巴结转移和远处转移)的敏感度为0.94(95% CI:0.79-0.99)。
临床怎么用
- 作者认为,临床医生、核医学医师和放射科医师可考虑在消化系统肿瘤的原发肿瘤、淋巴结转移和远处转移评估中使用[68Ga]Ga-FAPI PET/CT或PET/MR。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Digestive system tumors are a group of tumors with high incidence in the world nowadays. The assessment of digestive system tumor metastasis by conventional imaging seems to be unsatisfactory. [68Ga]Ga-FAPI, which has emerged in recent years, seems to be able to evaluate digestive system tumor metastasis. We aimed to summarize the current evidence of [68Ga]Ga-FAPI PET/CT or PET/MR for the assessment of primary tumors, lymph node metastases, and distant metastases in digestive system tumors. Besides, we also aimed to perform a meta-analysis of the sensitivity of [68Ga]Ga-FAPI PET diagnosis to discriminate between digestive system tumors, primary lesions, and non-primary lesions (lymph node metastases and distant metastases). MATERIALS AND METHODS: PubMed, MEDLINE and Cochrane Library databases were searched from the beginning of the database build to August 12, 2022. All studies undergoing [68Ga]Ga-FAPI PET for the evaluation of digestive tumors were included in the screening and review. Screening and full text review was performed by 3 investigators and data extraction was performed by 2 investigators. Risk of bias was examined with the QUADAS-2 criteria. Diagnostic test meta-analysis was performed with a random-effects model. RESULTS: A total of 541 studies were retrieved. Finally, 22 studies were selected for the systematic review and 18 studies were included in the meta-analysis. In the 18 publications, a total of 524 patients with digestive system tumors, 459 primary tumor lesions of digestive system tumors, and 1921 metastatic lesions of digestive system tumors were included in the meta-analysis. Based on patients, the sensitivity of [68Ga]Ga-FAPI PET for the diagnosis of digestive system tumors was 0.98 (95% CI: 0.94-0.99). Based on lesions, the sensitivity of [68Ga]Ga-FAPI PET for the diagnostic evaluation of primary tumor lesions of the digestive system was 0.97 (95% CI: 0.93-0.99); the sensitivity of [68Ga]Ga-FAPI PET for the diagnostic evaluation of non-primary lesions (lymph node metastases and distant metastases) of the digestive system tumors was 0.94 (95% CI: 0.79-0.99). CONCLUSION: [68Ga]Ga-FAPI PET has high accuracy and its sensitivity is at a high level for the diagnostic evaluation of digestive system tumors. Clinicians, nuclear medicine physicians, and radiologists may consider using [68Ga]Ga-FAPI PET/CT or PET/MR in the evaluation of primary tumors, lymph node metastases, and distant metastases in digestive system tumors.
引用
- Huang D, Wu J, Zhong H, et al. [68Ga]Ga-FAPI PET for the evaluation of digestive system tumors: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2022. PMID: 36326867. doi:10.1007/s00259-022-06021-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。